SALT LAKE CITY--(BUSINESS WIRE)--RemedyMD® Inc., leading provider of clinical and translational research solutions, today announced an agreement with The ALS Association’s research department, which will implement RemedyMD’s Investigate™ research software suite in three phases across TREAT ALS™, its translational research portfolio. Investigate’s Web-based technology enables full grant management and researcher collaboration, as well as the aggregation, mining, and cross-referencing of data. The goal is to increase commercialization opportunities and translate research results more rapidly into effective treatments.
